Genmab — Februar 2022
-
update of the EPCORE CLL-1 trial, adding 1 arm to focus on Richter's Syndrome https://clinicaltrials.gov/ct2/history/NCT04623541?A=3&B=4&C=merged#StudyPageTop https://www.cancerresearchuk.org/about-cancer/non-hodgkin-lymphoma/types/richters-syndrome
-
New spanish Maintenance trial with Bortezomib Plus Daratumumab (V-Dara) https://clinicaltrials.gov/ct2/show/NCT05218603
-
EL is the ØU analysis available now?
-
God morgen.
-
Asien: Markant positiv positiv påvirkning fra Wall Street - NY
https://www.proinvestor.com/investornyt/774792/asien-markant-positiv-positiv-pavirkning-fra-wall-street-ny -
Onsdagens aviser med Novozymes, Danske Bank og FLSmidth - NY
https://www.proinvestor.com/investornyt/774796/onsdagens-aviser-med-novozymes-danske-bank-og-flsmidth-ny -
Obligationer/tendens: Fortsat høj rente i sigte med fokus på inflation
https://www.proinvestor.com/investornyt/774799/obligationer-tendens-fortsat-hoj-rente-i-sigte-med-fokus-pa-inflation -
-
Pretty strong acceleration
-
I stand by that assumption. We are gonna get close to a third BB i 2022 ?
-
or no 3 and 4
-
Aktier/tendens: Novo kan klare sig bedre end ellers grønt marked
https://www.proinvestor.com/investornyt/774816/aktier-tendens-novo-kan-klare-sig-bedre-end-ellers-gront-marked -
Åbner vi over 2300? Ja det må tiden jo vise, men det blive nok grønt
-
Aktier/åbning: Novo og Ørsted i udbrud i grønt C25
https://www.proinvestor.com/investornyt/774828/aktier-abning-novo-og-orsted-i-udbrud-i-gront-c25
)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind